Market Overview

UPDATE: Citigroup Reiterates Illumina at Neutral on Valuation

Related ILMN
Goldman Says These 25 Healthcare Stocks Are Immune To The Election
Benzinga's M&A Chatter for Monday, October 17, 2016
Baron Funds Comments on Illumina Inc. (GuruFocus)

Citigroup maintained Illumina (NASDAQ: ILMN) at Neutral with a $51 price target.

Citigroup commented, "We expect the stock to be under pressure today as investors question the deal valuation/near-term $0.20 EPS dilution of the Verinata deal, the longer term impact of ILMN competing with its own customers (i.e., SQNM), and the level (if any) of Roche takeout premium to still ascribe to the stock. We remain on the sidelines on ILMN stock given the stock's current multiple and level of investment required/EPS power for the company in 2013."

Illumina closed at $54.76 on Friday.

Latest Ratings for ILMN

Oct 2016CitigroupMaintainsNeutral
Oct 2016BarclaysMaintainsEqual-Weight
Oct 2016Janney CapitalDowngradesNeutralSell

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Reiteration Intraday Update Analyst Ratings


Related Articles (ILMN)

View Comments and Join the Discussion!